Compare Lucid Group Inc (LCID) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lucid Group Inc vs Twist Bioscience Corp — how do they compare? Lucid Group Inc trades at $3.79 (market cap $1.51B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 6.7× Lucid Group Inc's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lucid Group Inc for 45 Days and Twist Bioscience Corp for 27 Days on average.
| LCID | TWST | |
|---|---|---|
Market Cap | $1.51B | $10.08B |
Volume | 12,333,745 | 4,229,037 |
Sector | Consumer Cyclical | Health |
52-Week High | $21.92 | $205.00 |
52-Week Low | $3.82 | $25.45 |
Typical Hold Time | 45 Days | 27 Days |
Enterprise Value | $4.40B | $10.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lucid Group (LCID) trades at $3.82, down 1.8% on the day, with a bearish technical signal and weak fundamentals. The company reported a net loss of $2.70 billion in 2025, with negative gross and net income margins, and has missed earnings expectations for three consecutive quarters. Recent news highlights cost-saving initiatives and autonomous vehicle partnerships, but also delays in the Cosmos SUV launch and concerns over cash burn.
The outlook remains challenging due to persistent losses and high cash burn, though analyst consensus suggests potential upside with a $7.60 price target. Key risks include execution delays, competitive pressures, and the need for additional financing. Investor sentiment is cautious, with most analysts rating the stock Hold.
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
